Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Japan Seeks ¥20 Billion In Spending Cuts With Generic Utilization

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Japan Prime Minister Taro Aso's government Dec. 16 unveiled a draft proposal to finance natural social security expenditures growth in fiscal 2009 partly with ¥20 billion in spending cuts for prescription drugs by encouraging the use of generic drugs

You may also be interested in...



Japanese Pharma Expects New Deal Model For Next 20 Years - New York Pharma Forum

NEW YORK - When the New York Pharma Forum, a group consisting primarily of Japanese pharmaceutical executives, gathered for its 20th General Assembly, members reflected on their companies' early days in the U.S. and their prospects for the future, when the scope of partnerships between Western pharma and Asia Pacific pharma will begin to change

Japanese Pharma Expects New Deal Model For Next 20 Years - New York Pharma Forum

NEW YORK - When the New York Pharma Forum, a group consisting primarily of Japanese pharmaceutical executives, gathered for its 20th General Assembly, members reflected on their companies' early days in the U.S. and their prospects for the future, when the scope of partnerships between Western pharma and Asia Pacific pharma will begin to change

Japan’s Slow Generic Use Caused By Physician Attitudes, Survey Says

TOKYO - Generic drugs' penetration into the Japanese pharmaceutical market has been languishing below 20 percent, and as many as 83 percent of consumers said their physicians have not recommended they switch from brand drugs, according to a survey released by research firm Ishare, Oct. 20

Latest Headlines
See All
UsernamePublicRestriction

Register

SC067466

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel